Creo Medical Group (LON:CREO) Shares Down 1.8% – Time to Sell?

Creo Medical Group PLC (LON:CREO)’s stock price dropped 1.8% on Thursday . The stock traded as low as GBX 13.50 and last traded at GBX 13.50. Approximately 2,707,456 shares traded hands during mid-day trading, an increase of 209% from the average daily volume of 875,276 shares. The stock had previously closed at GBX 13.75.

Analyst Ratings Changes

Separately, Shore Capital Group reissued a “house stock” rating and set a GBX 40 price target on shares of Creo Medical Group in a research report on Tuesday, May 26th.

Creo Medical Group Price Performance

The firm has a 50-day simple moving average of GBX 12.81 and a two-hundred day simple moving average of GBX 12.61. The company has a market capitalization of £65.58 million, a price-to-earnings ratio of 13.50 and a beta of 1.62. The company has a current ratio of 3.22, a quick ratio of 2.19 and a debt-to-equity ratio of 8.20.

Creo Medical Group (LON:CREO) last released its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. The company had revenue of GBX 600 million for the quarter. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%. As a group, analysts predict that Creo Medical Group PLC will post -10.0800005 earnings per share for the current fiscal year.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.